H E Lebovitz

Summary

Publications

  1. ncbi Type 2 diabetes: an overview
    H E Lebovitz
    SUNY Downstate Medical Center, 450 Clarkson Ave, Box 1205, Brooklyn, NY 11203, USA
    Clin Chem 45:1339-45. 1999
  2. ncbi Oral therapies for diabetic hyperglycemia
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
    Endocrinol Metab Clin North Am 30:909-33. 2001
  3. ncbi Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    H E Lebovitz
    Department of Medicine, State University of New York, Brooklyn, New York 11203, USA
    J Clin Endocrinol Metab 86:280-8. 2001
  4. ncbi Effect of the postprandial state on nontraditional risk factors
    H E Lebovitz
    State University of New York Health Sciences Center, Brooklyn, New York 11203, USA
    Am J Cardiol 88:20H-5H. 2001
  5. ncbi New treatments of diabetes: the beta-amylin agonists
    H E Lebovitz
    Health Science Center at Brooklyn, Endocrinology and Metabolism/Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Ann Endocrinol (Paris) 69:147-50. 2008

Collaborators

Detail Information

Publications5

  1. ncbi Type 2 diabetes: an overview
    H E Lebovitz
    SUNY Downstate Medical Center, 450 Clarkson Ave, Box 1205, Brooklyn, NY 11203, USA
    Clin Chem 45:1339-45. 1999
    ..Long-term glycemic control in type 2 diabetes requires progressive, stepwise, combination treatment with oral agents and eventually combination treatment with oral agents and insulin...
  2. ncbi Oral therapies for diabetic hyperglycemia
    H E Lebovitz
    Department of Medicine, State University of New York Health Science Center at Brooklyn, Brooklyn, New York, USA
    Endocrinol Metab Clin North Am 30:909-33. 2001
    ..In choosing combinations of oral antihyperglycemic agents, their effects on the components treatment of type 2 diabetic patients. These classes improve glucose considered, as must the specific effects of the agents on glucose metabolism...
  3. ncbi Rosiglitazone monotherapy is effective in patients with type 2 diabetes
    H E Lebovitz
    Department of Medicine, State University of New York, Brooklyn, New York 11203, USA
    J Clin Endocrinol Metab 86:280-8. 2001
    ..In the short-term, rosiglitazone is an insulin sensitizer that is effective and safe as monotherapy in patients with type 2 diabetes who are inadequately controlled by lifestyle interventions...
  4. ncbi Effect of the postprandial state on nontraditional risk factors
    H E Lebovitz
    State University of New York Health Sciences Center, Brooklyn, New York 11203, USA
    Am J Cardiol 88:20H-5H. 2001
    ....
  5. ncbi New treatments of diabetes: the beta-amylin agonists
    H E Lebovitz
    Health Science Center at Brooklyn, Endocrinology and Metabolism/Diabetes, State University of New York, 450 Clarkson Avenue, Brooklyn, NY 11203, USA
    Ann Endocrinol (Paris) 69:147-50. 2008